Get started
Author

Florence Meyer-Losic

Observed names: F Meyer-Losic, F. Meyer-Losic, F. Meyer-losic, Florence Meyer-losic, Florence Meyer‐Losic
Institution: Ipsen (France)
ORCID: 0000-0003-0245-2855
Observed ORCID: 0000-0003-0245-2855
OpenAlex ID: A5019295463
DTS-108, A Novel Peptidic Prodrug of SN38: In vivo Efficacy and Toxicokinetic Studies
2008 · Florence Meyer-Losic, Céline Nicolazzi, et al. · Clinical Cancer Research · 71
PDF
Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
2001 · N Guilbaud, L Kraus-Berthier, et al. · PubMed · 63
Improved Therapeutic Efficacy of Doxorubicin through Conjugation with a Novel Peptide Drug Delivery Technology (Vectocell)
2006 · Florence Meyer-Losic, Jérôme Quinonero, et al. · Journal of Medicinal Chemistry · 56
Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin
2008 · Denis Ravel, Vincent Dubois, et al. · Clinical Cancer Research · 29
PDF
STX140, but Not Paclitaxel, Inhibits Mammary Tumour Initiation and Progression in C3(1)/SV40 T/t-Antigen Transgenic Mice
2013 · Florence Meyer-Losic, Simon P. Newman, et al. · PLoS ONE · 24
PDF
Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer
2016 · Jessica Nakhlé, Valérie Pierron, et al. · OncoImmunology · 17
PDF
A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells
2019 · Serge Auvin, Harun Öztürk, et al. · Life Science Alliance · 15
PDF
Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
2023 · Sandrine Barbier, Benjamin Beaufils, et al. · Oncology and Therapy · 14
PDF
Comparison of the Anti-Tumour Activity of the Somatostatin Receptor (SST) Antagonist [177Lu]Lu-Satoreotide Tetraxetan and the Agonist [177Lu]Lu-DOTA-TATE in Mice Bearing AR42J SST2-Positive Tumours
2022 · Pascale Plas, Lorenzo Limana, et al. · Pharmaceuticals · 12
PDF
Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
2022 · Niranjan Awasthi, Margaret A. Schwarz, et al. · Molecular Cancer Therapeutics · 7
NTSR1 glycosylation and MMP dependent cleavage generate three distinct forms of the protein
2023 · Fotine Libanje, Raphael Delille, et al. · Scientific Reports · 4
PDF
On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models
2023 · Hélène Savel, Sandrine Barbier, et al. · Cancer Research Communications · 4
PDF
Differentiation of liposomal irinotecan from dose-dense non-liposomal irinotecan in patient-derived pancreatic cancer xenograft tumor models.
2020 · Sandrine Barbier, Stephane Lezmi, et al. · Journal of Clinical Oncology · 3
Statistical classification of treatment responses in mouse clinical trials for stratified medicine in oncology drug discovery
2024 · Hélène Savel, Florence Meyer-Losic, et al. · Scientific Reports · 2
PDF
Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
2019 · R. Sparks, S. Rolland, et al. · Annals of Oncology · 2
Tyrosine kinase inhibitor cabozantinib impacts dendritic and natural killer cells immune response in C38 syngeneic tumor model
2023 · Jordane Divoux, Sylvie Rolland, et al. · European Journal of Immunology · 1
PDF
Abstract 553: Antitumor efficacy of a liposomal formulation of irinotecan in preclinical gastric cancer models: Augmenting its response by antiangiogenic agents
2020 · Niranjan Awasthi, Margaret A. Schwarz, et al. · Cancer Research · 1
Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumor mouse models
2018 · S. Rolland, S.G. Klinz, et al. · Annals of Oncology · 1
[New approaches in experimental cancerology: in search of therapeutic models].
2001 · N Guilbaud, L Kraus-Berthier, et al. · PubMed · 1
Author response for "Tyrosine kinase inhibitor cabozantinib impacts dendritic and natural killer cells immune response in C38 syngeneic tumor model"
2023 · Jordane Divoux, Sylvie Rolland, et al. · Publons reviews and discussion
Supplementary Data S2 from On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models
2023 · Hélène Savel, Sandrine Barbier, et al.
Abstract 5044: Antitumor activity comparison of two somatostatin receptor ligands radiolabeled with Lutetium-177 (SSO110 and DOTA-TATE) alone or combined with chemotherapy in mice bearing AR42J SST2-positive tumors
2023 · Olivier Raguin, Marcel Krüger, et al. · Cancer Research
Supplementary Data S4 from On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models
2023 · Hélène Savel, Sandrine Barbier, et al.
Supplementary Data S3 from On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models
2023 · Hélène Savel, Sandrine Barbier, et al.
Supplementary Data S1 from On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models
2023 · Hélène Savel, Sandrine Barbier, et al.
Works count: 54
Citation count: 327
H-index: 9
I10-index: 9
Year
Topic
Type